A Daily Weight-Loss Pill Worked Just as Well for Women at Every Stage of Menopause, New Trial Data Show

A daily oral weight-loss drug called orforglipron produced similarly large reductions in body weight for women regardless of their menopausal stage, according to new subgroup analyses of the Phase 3 ATTAIN trials presented at the Annual Meeting of the European Association for the Study of Diabetes in Milan, which runs from 28 September to 2 October. The findings were reported by HCPLive and by Pharmacy Times.

Why menopause complicates weight-loss research

Menopause is well documented to make weight management harder for many women, as shifting hormone levels change how the body stores fat and regulates appetite, which has made researchers and clinicians cautious about assuming a weight-loss drug's effects will carry over evenly across premenopausal, perimenopausal and postmenopausal patients without dedicated data. The new analyses, drawn from the ATTAIN-1 and ATTAIN-2 trials, were built specifically to test whether orforglipron's benefit holds up once patients are split into those three groups rather than treated as a single population.

What the numbers showed

Across both trials, women taking orforglipron saw body weight reductions of up to 14 per cent, with the size of that effect remaining statistically similar whether a participant was premenopausal, actively going through menopause, or postmenopausal. Responder rates told a consistent story: up to 83 per cent of women on orforglipron achieved at least a 5 per cent reduction in body weight, compared with roughly 23 per cent of those on placebo, and higher thresholds of 10, 15 and 20 per cent weight loss also favoured the drug by wide margins across every subgroup.

Beyond the scale

The analyses also tracked waist circumference, finding reductions of up to 12.5 centimetres among women taking orforglipron, again with the benefit holding steady across menopausal subgroups rather than concentrating in one life stage. That consistency matters clinically because waist circumference is closely tied to metabolic risk factors such as insulin resistance, and a drug whose benefit narrows sharply after menopause would be a meaningfully different clinical proposition than one whose effect holds steady throughout a woman's reproductive lifespan.

What sets orforglipron apart from injectable competitors

Unlike semaglutide and tirzepatide, which are delivered by injection, orforglipron is an oral, non-peptide GLP-1 receptor agonist, meaning it can be taken as a daily pill rather than requiring a weekly injection, a distinction that matters for patients who are needle-averse or for health systems trying to simplify distribution and storage. Its developer has positioned the drug as a candidate for wider, easier-to-scale use in obesity and type 2 diabetes care if regulators approve it, and menopause-specific efficacy data of the kind presented in Milan is the sort of evidence payers and prescribers typically want before recommending a drug broadly to a population as large as postmenopausal women with obesity.

What is still unproven

These are subgroup analyses of existing Phase 3 trial data rather than a dedicated new trial enrolling women at defined menopausal stages from the outset, so the comparison, while informative, was not the primary question either ATTAIN study was originally designed to answer. Longer-term data on durability of weight loss, on any interaction with hormone therapy some menopausal women also take, and on regulatory approval itself all remain outstanding, but the consistency across three biologically distinct subgroups is the kind of result that tends to reassure clinicians who had reason to expect a weaker effect after menopause.